Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487077 | 1.00 | NR1H2 (1.00) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3487794 | 0.99 | NR1H2 (0.98) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3486754 | 0.90 | NR1H2 (0.82) | NR1H2NR1H3MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3488079 | 0.83 | NR1H2 (0.71) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3488448 | 0.81 | NR1H2 (0.68) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3487932 | 0.79 | NR1H2 (0.65) | NR1H2NR1H3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL3488864 | 0.79 | NR1H2 (0.65) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3487298 | 0.77 | NR1H2 (0.62) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3488247 | 0.76 | NR1H2 (0.62) | NR1H2NR1H3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3487254 | 0.75 | NR1H2 (0.60) | NR1H2NR1H3MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| CN-119112854-A | Application of agonist for targeting LXR alpha in liver macrophages | 中国人民解放军军事科学院军事医学研究院 | 2024-12-13 | — | — | CN | claimed |
| WO-2024228596-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | (주) 멥스젠 | 2024-11-07 | — | — | WO | claimed |
| EP-4373922-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| CN-117677691-A | Methods and compositions for the generation of human midbrain neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-20230027059-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2023-01-26 | — | — | US | claimed |
| WO-2023003621-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-01-26 | — | — | WO | claimed |
| EP-3999055-A1 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-05-25 | — | — | EP | claimed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | claimed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | claimed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | disclosed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025059405-A1 | COMPOSITIONS FOR USE IN A METHOD OF TREATING A MOTOR NEURON DISEASE OR CONDITION ASSOCIATED WITH A SPG11 PATHOGENIC VARIANT | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20220257596-A1 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-08-18 | — | — | US | disclosed |
| EP-3999055-A1 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257596-A1 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H2 3/4885NR1H3 2/4885NPC1 233/4885 |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885NPC1 98/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885NPC1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.